These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21366638)

  • 21. Safety of infliximab use during pregnancy.
    Djokanovic N; Klieger-Grossmann C; Pupco A; Koren G
    Reprod Toxicol; 2011 Jul; 32(1):93-7. PubMed ID: 21621603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exposure to Infliximab During Pregnancy: Post-Marketing Experience.
    Geldhof A; Slater J; Clark M; Chandran U; Coppola D
    Drug Saf; 2020 Feb; 43(2):147-161. PubMed ID: 31677004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.
    Deepak P; Stobaugh DJ
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1035-43. PubMed ID: 25164260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy.
    Kane SV; Acquah LA
    Am J Gastroenterol; 2009 Jan; 104(1):228-33. PubMed ID: 19098873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
    Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
    Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
    Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
    Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
    J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
    Koutroubakis IE; Oustamanolakis P; Malliaraki N; Karmiris K; Chalkiadakis I; Ganotakis E; Karkavitsas N; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):283-8. PubMed ID: 19279474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pregnancy and inflammatory bowel disease: a prospective case-control study.
    Malgarinos G; Gikas A; Delicha E; Stamataki A; Georgopoulos F; Papadimitriou A; Stanciu C; Triantafillidis JK
    Rev Med Chir Soc Med Nat Iasi; 2007; 111(3):613-9. PubMed ID: 18293689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intentional infliximab use during pregnancy for severe steroid-refractory ulcerative colitis.
    Aratari A; Margagnoni G; Koch M; Papi C
    J Crohns Colitis; 2011 Jun; 5(3):262. PubMed ID: 21575893
    [No Abstract]   [Full Text] [Related]  

  • 31. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ;
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Inflammatory bowel disease and pregnancy].
    Parfenov AI
    Eksp Klin Gastroenterol; 2012; (3):80-6. PubMed ID: 22830229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory bowel disease and pregnancy: report of two cases treated with infliximab and a review of the literature.
    Correia LM; Bonilha DQ; Ramos JD; Ambrogini O; Miszputen SJ
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1260-4. PubMed ID: 20671559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-TNF therapy in inflammatory bowel diseases during pregnancy and breast-feeding].
    Persić M
    Acta Med Croatica; 2013 Apr; 67(2):157-64. PubMed ID: 24471298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.
    Grišić AM; Dorn-Rasmussen M; Ungar B; Brynskov J; Ilvemark JFKF; Bolstad N; Warren DJ; Ainsworth MA; Huisinga W; Ben-Horin S; Kloft C; Steenholdt C
    United European Gastroenterol J; 2021 Feb; 9(1):91-101. PubMed ID: 33079627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are anti-TNF drugs safe for pregnant women with inflammatory bowel disease?
    Brennan GT; Duong A; Nguyen ET; Nguyen DL
    Cleve Clin J Med; 2018 Dec; 85(12):923-924. PubMed ID: 30526752
    [No Abstract]   [Full Text] [Related]  

  • 38. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?
    Chaparro M; Gisbert JP
    Expert Opin Drug Saf; 2014 Dec; 13(12):1749-62. PubMed ID: 25244582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammatory bowel disease: management issues during pregnancy.
    Ferrero S; Ragni N
    Arch Gynecol Obstet; 2004 Sep; 270(2):79-85. PubMed ID: 12721680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring vital signs during infusion with infliximab does neither indicate nor predict development of acute infusion reactions.
    de Vries HS; van Oijen MG; van Hoven-van Loo KE; de Jong DJ
    J Clin Gastroenterol; 2009 Apr; 43(4):387-8. PubMed ID: 18987555
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.